168 related articles for article (PubMed ID: 8976815)
21. [Amifostine: current and future applications in cytoprotection].
Lenoble M
Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
[TBL] [Abstract][Full Text] [Related]
22. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
23. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
24. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
25. Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
Rohilla S; Dureja H; Chawla V
Curr Cancer Drug Targets; 2019; 19(10):765-781. PubMed ID: 30914026
[TBL] [Abstract][Full Text] [Related]
26. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
27. Future directions in non-small cell lung cancer.
Schiller JH
Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
[TBL] [Abstract][Full Text] [Related]
28. [Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
Dtsch Med Wochenschr; 1996 Sep; 121(36 Suppl Fur Die):1-6. PubMed ID: 9417379
[No Abstract] [Full Text] [Related]
29. The current status of toxicity protectants in cancer therapy.
Schuchter LM; Luginbuhl WE; Meropol NJ
Semin Oncol; 1992 Dec; 19(6):742-51. PubMed ID: 1334280
[TBL] [Abstract][Full Text] [Related]
30. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
31. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
32. Amifostine and combined-modality therapeutic approaches.
Mehta MP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
[TBL] [Abstract][Full Text] [Related]
33. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
34. Current role of chemotherapy protectors in cancer treatment.
Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
36. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
37. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
38. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
39. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
40. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]